Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab vs Anti-TNF in RA
NCT03100253Phase 4Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Mar 2018
- Primary completion
- Dec 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Mario Negri Institute for Pharmacological Research. Started Mar 2018; status: terminated.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03100253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100253.